Kala Bio (LTS:0JQ2) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JQ2 Kala Bio Inc LTS:0JQ2
38 GF Score
Price $0.71
GF Value $1.98
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Kala Bio NonCurrent Deferred Liabilities?

Kala Bio LTS:0JQ2 -1.52% 38 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0JQ2 with a GF Score™ of 38/100 and a GF Value™ of $1.98 (Possible Value Trap). The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kala Bio's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Kala Bio NonCurrent Deferred Liabilities Related Terms

Kala Bio NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Kala Bio's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kala Bio NonCurrent Deferred Liabilities Chart

Kala Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.00 0.00 0.00 0.00

Kala Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0JQ2
38GF Score
Kala Bio Inc LTS:0JQ2
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Kala Bio (LTS:0JQ2) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kala Bio and its competitors.
Is Kala Bio's NonCurrent Deferred Liabilities too high?
Kala Bio's current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Kala Bio has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's NonCurrent Deferred Liabilities compare to GDTC and GTBP?
Kala Bio's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kala Bio and its competitors. Kala Bio's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Based on GuruFocus' analysis, Kala Bio (LTS:0JQ2) is currently considered Possible Value Trap. The stock's GF Value™ is $1.98, compared to a current price of $0.71 — trading 64% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.00 Mil. Kala Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Kala Bio (LTS:0JQ2), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kala Bio (LTS:0JQ2) Overvalued in 2026?

Based on GuruFocus' analysis, Kala Bio stock appears to be undervalued. The current stock price of $0.71 is trading 64% below its estimated GF Value™ of $1.98. GuruFocus considers Kala Bio to be Possible Value Trap.

Key valuation signals for LTS:0JQ2:

  • NonCurrent Deferred Liabilities: $0.00 Mil
  • GF Value™: $1.98 vs. price of $0.71 (64% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the LTS:0JQ2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kala Bio Business Description

Other Exchanges KALA:USA27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
38GF Score

Get the complete analysis for LTS:0JQ2

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$1.98
GF Value